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Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological
community, indicating potential detrimental effects on cancer patients. Our aim was to
summarize the converging key points providing a general guidance in order to support
decision making, pertaining to the oncologic care in the middle of a global outbreak.
Methods: We did an international online search in twenty five countries that have
managed a surge in cancer patient numbers. We collected the recommendations from
thirty one medical oncology societies.
Results: By synthesizing guidelines for a) oncology service delivery adjustments, b)
general and specific treatment adaptations, and c) discrepancies from guidelinesNovember 2020 | Volume 10 | Article 5751481
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Frontiers in Oncology | www.frontiersin.orgcomparison, we present a clinical synopsis with the forty more crucial statements. A
Covid-19 risk stratification base was also created in order to obtain a quick, objective
patient assessment and a risk-benefit evaluation on a case-by-case basis.
Conclusions: In an attempt to face these complex needs and due to limited
understanding of COVID-19, a variability of recommendations based on general
epidemiological and infectious disease principles rather than definite cancer-related
evidence has evolved. Additionally, the absence of an effective treatment or vaccine
requires the development of cancer management guidance, capitalizing on
comprehensive COVID-19 oncology experience globally.Keywords: Covid-19, recommendations, international, oncology, societiesINTRODUCTION
The rapid international spread of COVID-19,-linked to the severe
adult respiratory syndrome SARS-CoV-2- along with the
proliferation of severe morbidity cases, often leading to death, has
placed extremepressure onhealth care systems, necessitating global
coordination and collaboration between governments, healthcare
professionals andorganizations.Despite our poor understanding of
this new coronavirus, recommendations for the management of
specific patient groups were rapidly developed.
Preliminary reports identified the high risk of cancer patients
contracting COVID-19 and having a worse outcome than the
general population (1, 2). Cancer alone was associated with a
potential intensive care unit admission and death risk (OR 5.4,
95% CI 1.8–16.2) (1). This led to a rapid evolution of patients’
and clinicians’ guidance from national and international
oncology societies (3). The scientific evidence was- and is still-
missing though, and in many cases, this guidance was based on
extrapolation of information from previous pandemics, regional
guidance and logical judgements (4, 5).
Herein, we summarize the guidance provided so far from
medical oncology societies to allow a better interpretation and
implementation of proposed actions to face the evolution of the
COVID19 pandemic.METHODS
An established collaborative group of oncologists (6) provided
guidelines and recommendations from their national medical
societies for cancer management during COVID-19 and present
patients’ expectations from oncology societies, respectively.
Guidelines from individual institutes were not included, unless
it was the only cancer centre in the country, while oncology-
related state guidance was captured as well. Documents which
were exclusively patient-facing (i.e., did not provide guidance to
healthcare providers) were also excluded.
A typical medical literature search was not conducted due to
the sudden nature of the pandemic, the rapid and recent
production of the documents, and their frequent publication
outside of the medical literature (as for example on agency
websites). For reasons of urgency, the available documents2
were not produced using accepted guideline protocols, such as
AGREE II, and thus were not graded.
Results were summarized and compared by type of
recommendation (preventive, intervention, and treatment measures),
risk group and type of malignancy when applicable, with focus on
converging points, discrepancies, potential shortcomings, and
underlying evidence level.RESULTS
Medical oncology recommendations from 25 countries and 31
international organizations were analyzed (Appendix Table 1).
Oncology societies provided general and specific instructions to
revise cancer patient’s service delivery and treatment. The
development of a clear risk minimization strategy was common,
focusing on patients’ social contacting reduction. Below, we present
the convergingpoints fromdifferent societies classified in: a) guidelines
for oncology service delivery adjustments, b) general and specific
treatment adjustments, c) special issues guide, d) discrepancies from
guidelines comparison.
Service Delivery
Most societies agree on minimization of: hospital visits,
unavoidable visits duration and waiting areas overcrowding.
Service delivery recommendations include physical attendance
only when essential and substitution with “tele”-service. Similar
suggestions include: treatment prioritization strategies; stratified
follow-up models; follow-up visit postponement and use of tele-
consulting; slot appointment planning; waiting for appointments
in the car or other non-clinical areas; no escorts in clinical
facilities, unless essential (Appendix Table 2).
Furthermore, phone triage the day before treatment (as well as
before entering the facilities in checkpoint areas), waiting room
rearrangements with respect to social distancing and creation of a
separate circuit for theoncological patients are commonlyproposed
as measures to further reduce the risk of transmission (Appendix
Table 2).
Other recommendations include staff training to triage and test
patients, to isolate positive cases and use Personal Protective
Equipment, as well as patient guidance in preventive measures
and symptoms report (Appendix Table 2). Ways to involveNovember 2020 | Volume 10 | Article 575148
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proposed: virtual MDT attendance, telephone/video consultations
(especially for follow-ups), identificationof vulnerable patients, and
patients suitable for remote monitoring/follow-up and data
entry (7).
Reduced mobility and physical contacts of medical staff within
hospitals are also recommended. MDTs as well as other meetings
organization via video-applications is also advised; similarly, ward
rounds restriction to two doctors is recommended (8).
Medical Treatment: General
Considerations
Case by case decisions are proposed, and the continuation of anti-
cancer treatment should be individualized according to the patient’s
needs. Most societies agree on an upfront risk/benefit discussion
with the patient regarding treatment continuation. SEOM
recommends that it be documented in the informed consent,
with a clear description of the potential risks. MDT discussion
with the patient on cancer treatment adjustments is advisable (7).
A substantial limitation of physical contacts is a key point,
leading to several treatment adjustments, such as: treatments
delays/breaks when clinically appropriate or after discussion with
the patient; home blood specimen collection before treatment;
home deliveries of long-term treatment supplies and therapies for
low risk injectable and oral agents; tele-monitoring or repetitive
treatment; treatment interval increase by limiting the use of dose-
dense chemotherapy regimens and adjustment to the longest cycle
regimens possible; whenever applicable, change i.v. chemotherapy
to oral or subcutaneous forms. Supportive (e.g.bisphoshonates)
treatments could be delayed and blood transfusions limited to the
absolutely necessary (Appendix Table 3).
Aiming at immunosuppression risk reduction, many societies
[MOGA/AGCA, Bulgarian, Chinese, HDIO, IOL, SEOM, SOF/
RCCC, NHS/NICE, ASCO/NCCN/ACS/CDC, ESMO]
recommend the use of prophylactic GCSF +/- antibiotics (2, 9–
12) and also reducing or tapering steroids as anti-emetics or
immune-suppressants when appropriate. Dutch Oncology Society
(NVMO) is against the prophylactic use of GCSF +/- antibiotics
(13). SEOM suggests avoiding initiation of immunosuppressive
treatment in possibly infected patients, with a history of contacts at
risk orwhen 2-3weeks delay is not health-threatening; the plan can
be reviewed every 2–3 weeks by phone. BSMO suggests to critically
review theurgency for initiationofnewcancer therapy andconsider
postponement for several months; if 12 weeks postponement is not
feasible, contacts should go on as pre-planned (14).
In order to facilitate these decisions and prevent staff shortage
or infrastructure capacity overload at a potential second
pandemic outbreak, risk assessments and treatment
prioritization models were proposed by several societies (7, 15,
16) and are presented in Table 1.
Setting Specific Management
Certain societies provide specific treatment adjustments
guidance and additional detailed considerations by cancer type
and treatment setting. ESMO recently published detailed
management guidelines stratified by risk priority group- as
described above- and type/stage of malignancy (16).Frontiers in Oncology | www.frontiersin.org 3Invasive Procedures
The decision for the necessity for interventional radiology
procedures and diagnostic biopsies depends on its importance
in guiding subsequent treatment decisions and on the patient’s
co-morbidity. Curative primary tumour resections should not be
postponed or omitted. Metastasectomies or debulking surgeries
should be performed upon personalized risk-benefit evaluation.
A surgical procedure that could postpone (neo) adjuvant
chemotherapy should be considered.
Adjuvant and Neoadjuvant Treatment
As long as the goal is the cure, (neo)-adjuvant chemotherapy or
immunotherapy should not be postponed or omitted. However,
when the benefit is considered marginal, the risk for fatal
coronavirus infection should be weighed against the potential
benefit. Use of regimens with the longest cycle possible is
suggested. Adjuvant hormonal treatment should be continued.
Treatment for Metastatic Disease
Continuation of intravenous chemotherapy with or without
immunotherapy should be individualized. Maintenance
therapy could potentially be discontinued and treatment
holidays should be offered whenever appropriate. Palliative and
late line systemic treatments should be probably postponed or
adapted to the longest cycle regimen possible or switch to oral
regimens. Some agencies, i.e., CCO, have provided detailed
priority lists to facilitate treatment decisions by disease site.
Immunotherapy should be continued on basis of risk benefit
equation, with increased alertness for respiratory infection
symptoms. Hormone therapy treatment should be continued.
Treatment with CDK4/6 inhibitors should be re-evaluated and
discontinued if potential benefit is low or adjusted according to
immunosuppression risk. The benefit of mTOR inhibitors should
be evaluated on a case-by-case basis given the risk for pneumonitis.
Patients With Confirmed COVID-19
Infection: When to Go Back on Treatment?
There is limited evidence on the link between recent oncological
treatment and severe COVID-19 events (1, 17). It is also unclear
when to restart treatment after COVID-19 infection. ASCO
recommends to hold treatment until the patient is
asymptomatic or there is proof of infection resolution, but in
cases of severe cancer complication risk, restarting therapy is
advised. NICE suggests restarting treatment after one negative
SARS-Cov-2 test (7). Finally, French guidance recommends
treatment continuation after patient’s recovery (15). To date,
ESMO issued only a short statement suggesting for treatment
initiation or continuation for SARS-CoV2-positive cancer
patients if they are a- or pauci-symptomatic, still fit to be
treated and after proper risk/benefit analysis.
Furthermore, according to CDC, severely immuno-
compromised patients, after COVID-19 infection, can discontinue
transmission-based precautions after at least two negative
consecutive nasopharyngeal swab specimens collected ≥24 h
apart, when accompanied by fever resolution (without
medication) and respiratory symptoms improvement (18);
according to ASCO, it would be reasonable to initiate/resumeNovember 2020 | Volume 10 | Article 575148
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longer necessary. Still, given the limited data and the ongoing
research, further updates on this issue are expected.
Special Issues
Senior Patients
No specific guidance could be identified for this patient group,
with an approach proportional to the general population and
based on a documented risk assessment. ESMO suggests “more




bemanaged like the general population, any investigations with no
symptom control provision should be avoided and hospitalization
should be considered when needed (15). ESMO provides a detailed
prioritization list.An at-home service is preferable, while admission
should be offered in intensive interventions, especially in oncologic
emergencies (e.g., spinal cord compression, severe pain, etc.).
Clinical Trials
FDA and SEOM provide guidance on clinical trials conduction
during the pandemic, with focus on participants’ safety (14). The
continuation of an investigational product depends on individual
circumstances. Patients under treatment should limit per protocol-
specified visits. Alternative ways to assess/follow up patients areFrontiers in Oncology | www.frontiersin.org 4recommended after contacting with CRAs/sponsors (e.g., phone
contact, virtual visit, alternative location for assessment, including
local community labs or imaging centres). Inclusion of newpatients
should be considered on a case-by-case basis (19).
SEOM suggested that protocol’s recommendations should be
strictly followed with dose delays and adjustments as per protocol
but adapted to the healthcare and epidemiological situation. BSMO
suggested a continuation of ongoing trials, without on-site monitor
visits, but no new trials initiation (14). The Dutch and NICE
recommendations suggested to continue treatment for patients
already included within trials, but to stop recruitment (7, 8).
ESMO supports treatment continuation within a clinical trial,
provided that benefits outweigh risks, with a possible adaptation
of procedures without affecting patient’s safety and study conduct.
Ventilator Support and Resuscitation Status
The oncology treating team must inform the intensivist physicians
(ICU) on the need for intubation and ventilation. A detailed
description of the oncological status is crucial when curative
treatment is given (20). The Dutch recommendations suggest to
proactively discuss with the patients about the escalation level,
resuscitation status (DNR) and ventilation strict policies (8).
Well-Being and Emotional Resilience
ESMO and ASCO have addressed the importance of healthcare
providers’ mental well-being, with ASCO providing specific
suggestions on their mental health.TABLE 1 | Risk assessments and treatment prioritization models.
Priority
group
ESMO NICE HPSP HeSMO
1 Life threatening conditions, clinically
unstable pts or when benefit is higher than
risk in terms of survival or QoL (high priority
group)
Curative therapy with a high (>50%)
chance of success
Pts treated with curative intent:
≤60 y old or
life exp ≥5 y, or
both
Pts with imminent life threat: e.g.,
metastatic germ cell tumors,
aggressive neoplasms
2 Pts in non-critical status, whose
oncological treatment benefit qualifies for
intermediate priority: treatment should not
be delayed > 6 weeks as this could be
detrimental on the oncological outcome
Curative therapy with an intermediate (15–
50%) chance of success
Pts treated with non-curative
intent:
≤60 y old or
life exp ≥5 y, or
both,
and under early line of treatment
Pts with severe QoL deterioration
due to cancer symptoms and
high morbidity
3 Pts stable enough for their treatment to be
delayed for the duration of the pandemic
and/or when the intervention benefit is
minimal: no survival gain with no change
nor reduced QoL
(low priority group)
Non-curative therapy with a high (>50%)
chance of >1 yr life extension
Pts treated with non-curative
intent: those under PD or when
treatment interruption can be life
threatening
Pts undergoing therapy with
curative intent
4 Curative therapy with low (0–15%) chance
of success OR non-curative therapy with
an intermediate (15–50%) chance of > 1 y
life extension
Pts under palliative therapy but
with significant survival benefit
5 Non-curative therapy with a high (>50%)
chance of palliation/temporary tumor
control but < 1 year life extension
Pts under palliative therapy with
modest survival benefit with/or
significant symptoms control
6 Non-curative therapy with an intermediate
(15–50%) chance of palliation and
temporary tumor control with < 1 y life
extension.
Pts under palliative therapy
without survival benefit or
symptom control
7 Supportive measures or cases
where therapy does not affect
patient outcomeNovember 20Pts, patients; exp, expectancy, y, year.20 | Volume 10 | Article 575148
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Reliable information from scientifically driven sources should be
followed, while using or sharing social media accounts and
rumours should be critically appraised (16).
Ethics
Expectations that the pandemic may constrain resources has led
to the recommendation of care prioritization based on expected
outcomes. The ethical framework has been provided by some
documents, providing support for communication with patients
and families when limitations are required [CCO, BCC].Discrepancies Between the Guidelines
Bone Marrow Growth Factor Therapy
Generally, guidelines support the use of prophylactic G-CSF in order
to decrease the risk of hospital admission due to neutropenic sepsis
that could exposepatients toCovid-19 infectionanddiverthealthcare
resources (Appendix Table 3) (2, 9–13). However, Dutch guide
recommends against G-CSF use given the unclear impact on
COVID-19-infection and potential increase of risk for acute
respiratory distress syndrome (14). Further research is required to
determine the effect of G-CSF during Covid-19 (2, 9–14).Immunotherapy
The risks for patients on immune checkpoint inhibitors and CTLA4
antagonists from COVID-19 infection are also uncertain as the
significance of the resulting immune effect on clinical outcome is
currently debatable (2, 20–23). Still, their potential toxicity profile,
including respiratory morbidity creates concerns. According to
ESMO, close monitoring for specific symptoms, e.g., pneumonitis
or infection, is recommended, to allow prompt withdrawal of
treatment and possible referral to COVID-19 diagnostic pathway.
ASCO gives no guide for immunotherapy since no reliable evidence
is available and suggests literature follow-up.Personal Protective Equipment (PPE)
Face mask use has been a conflicting point, but now there is
mostly a consensus on mask use both by medical staff, patients
and relatives during hospital visits See also Appendix Table 4.DISCUSSION
The COVID-19 pandemic has led to the adaptation of new
clinical strategies aiming at physical contacts minimization and
adoption of tele-practising models. The oncologists’ challenge is
to provide effective treatment and support cancer patients. A
plethora of clinical practice guidances has rapidly developed,
agreeing on the main changes to be implemented.
The oncologic society’sfirst priority has been the implementation
of an upfront strategy based on safety and treatment efficacy.
However, strategic measures derive from general epidemiologic
and infectious disease knowledge from prior epidemics (4, 5),Frontiers in Oncology | www.frontiersin.org 5which is still poor in the case of COVID-19. Yet, continuous
research begins to offer a better understanding of the new
coronavirus (24–26). Due to the lack of definitive evidence on the
COVID-19 exact pathological profile, guidelines bydifferent societies
mayvary in specific areas,withone example being the controversy on
face mask use, at least until recently (27).
Even more challenging has been the guidance about the use of
G-CSF (2, 9–13). Potential benefits may arise from reducing the
likelihood of hospital admission due to chemotherapy induced
neutropenic fever or sepsis. However, neutrophilia and neutrophil-
to-lymphocyte ratios predict poor outcomes in patients with
COVID-19 (11, 28). Neutrophilia could be a source of excess
neutrophil extracellular traps (NETs); the formation of which can
drive a variety of severe pathologies in the lungs, induce mucus
accumulation in airways and drive ARDS (29). NETs are also
implicated in the development of arterial and venous thrombosis, a
feature observed in individuals with severe COVID-19 infection
(30). Furthermore, severe COVID-19 is associated with increased
plasma concentrations of pro-inflammatory cytokines (cytokine
storm) and other molecules including G-CSF (31, 32). Taken
together, these data generate uncertainty on the risk/benefit
balance concerning the use of G-CSF (2, 9–13).
Whereas many of the recommendations for cancer treatment
relate to cytotoxic chemotherapy, guidance onnewer therapies, e.g.,
immune checkpoint CDK4/6, mTOR, and PARP inhibitors,
appears only intermittently. For these treatments, we are only
based on basic clinical science to help predict possible
consequences of COVID-19 infection. Additionally, some of
these treatments have adverse effects, like pneumonitis or severe
myocarditis, that simulate symptoms arising from COVID-19
infection, posing a threat to appropriate clinical management and
possibly compromising survival (33). Currently, most society
guidelines suggest a continuation of such treatments upon
individualized risk/benefit assessment, but scientific validation
is awaited.
It should be emphasized that currently there is a significant lack
of specific guidance required for patients with, or recovering from
COVID-19 and needing to initiate or restart cancer treatment.
ASCO and NICE have published generic guidance, while others
(ESMO,French society) have a short comment, leaving the decision
making to individual clinical evaluation. Urgent development is
needed in: virus testing method and frequency, confirmatory tests,
definition of adequate asymptomatic period, management of
persisting COVID-19 positivity and evaluation of potential risk
stratification factors.
Oneof the greatest challenges is how toadvise cancerpatients on
COVID-19 risks when there is a lack of evidence in this matter.
Though some patients may appreciate the clinician’s honesty,
others may leave it to their doctor to make the judgement call (34).
We should not forget that, as with previous pandemics,
COVID-19 may present subsequent infection peaks, influenced
by factors such as seasonal and regional variation (35, 36). In the
Northern Hemisphere countries are still heavily affected by the
pandemic and any relaxation of the first phase stringent
measures may result in a second surge within the coming
months. Additionally, concerns are raised about COVID-19’sNovember 2020 | Volume 10 | Article 575148
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medical and economic resources to counteract the threat.
As our understanding of COVID-19 grows, management
approaches may be intensified, added, dropped or permanently
implemented in our clinical practice. During data collection for
this report we noticed changes in the available guidelines, and
expect further evolution to a more permanent adapted model.CONCLUSIONS
Oncological societies have quickly developed and adapted
recommendations in these unprecedented circumstances. As
clinicians, we strive to provide the best cancer management
and treatment in the face of COVID-19 uncertainties (37).Frontiers in Oncology | www.frontiersin.org 6AUTHOR CONTRIBUTIONS
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Kamposioras et al. Covid-19 Recommendations From International Oncology SocietiesAPPENDIX TABLE 1 | Guidelines demographics across screened societies *
Country/Region Society Acronyms (Abbreviations) Guidance
Australia Medical Oncology Group of Australia MOGA Y
Australian Government-Cancer Australia AG-CA Y
Austria Austrian Society for Hematology and Medical Oncology ÖGHO Onkopedia
Belgium Belgian Society of Medical Oncology BSMO Y
Brazil Sociedade Brasileira de Oncologia Clıńica SBOC Y
Bulgaria Bulgarian National Association of Oncology BNAO –
Bulgarian Association of Medical Oncology BAMO –
Expert Council Panel Y
Canada Cancer Care Ontario CCO Y
British Columbia Cancer BCC Y
China Breast Cancer expert committee, National Cancer Quality control Center NCQC-BC Y
Croatia Croatian Society for Medical Oncology HDIO Y
Cyprus Cyprus Oncology Society OEK Y
HeSMO, ASCO
Czech Republic Czech Society for Oncology CSO Y
France Haut Conseil de Santé Publique HPSP Y
Germany Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie DGHO Onkopedia
Greece Hellenic Society of Medical Oncology HESMO Y
Italy Italian Association of Medical Oncology AIOM Y
Japan Japanese Society of Medical Oncology JSMO ASCO
Jordan Jordanian Oncology Society JOS NCCN, ASCO
Netherlands Nederlandse Vereniging voor Medische Oncologie NVMO# Y
Portugal Sociedade Portuguesa de Oncologia SPO Y
Serbia Serbian Society for Medical Oncology UMOS ESMO
Slovenia Institute of Oncology Ljubljana IOL# Y
Slovenian Society of Medical Oncology SIO ESMO, ASCO
Spain Sociedad Española de Oncologıá Médica SEOM Y
Sweden Swedish Society of Oncology—Svensk Onkologisk Förening SOF# Y
Regional Cancer Centre in Cooperation RCCC Y
Switzerland Swiss Society of Medical Oncology SSMO·SSOM·SGMO Onkopedia
UK National institute for health and care excellence NICE Y
USA American Society of Clinical Oncology ASCO Y
National Comprehensive Cancer Network NCCN Y
Europe European Society for Medical Oncology ESMO YFrontiers in Oncology | www.frontiersin.org 8 November 2020 | Volume 10Data cut-off for screening of National Societies and International Societies was April 30, 2020.
#Guidelines available only for members of the society
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Y Y (AHM) Y (AMC) Y – Y (AHM) Y
((AHM)
Y (AMC) Y (AMC)
Belgium
BSMO
– – Y Y – – Y – –





Y Y Y Y Y Y Y Y Y
Canada
CCO
Y – Y Y Y – Y Y –
Canada
BCC
Y Y Y Y Y Y Y – –
China Y Y Y Y Y Y Y Y Y
Croatia
HDIO
– Y Y Y Y Y Y Y
Cyprus
OEK






Y Y * Y* Y Y * Y* Y* Y* Y*
France
HPSP




– – Y – – – – –
Greece
HESMO
Y Y Y Y Y – Y Y Y
Italy AIOM Y ( for high risk
regions)
Y Y Y Y Y Y
Netherlands
NVMO
Y Y Y Y
Portugal
SPO
Y Y Y Y Y – Y – Y
Slovenia IOL Y Y Y Y Y Y Y Y Y
Spain SEOM Y – Y Y – – – Y Y
Sweden
SOF, RCCC
Y Y Y Y – – – – –





– Y Y Y Y Y Y – Y
Europe
ESMO
– – Y y Y Y# Y# Y# Y#
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– – Y – Y Y Y Y –
Canada
CCO
– Y – – – – – – –
Canada
BCCA
– Y – – – – – – –
China Y Y Y Y Y Y Y Y Y
Croatia
HDIO
– – – – – Y Y – Y
Cyprus
OEK






– – – Y * Y* Y* – – Y*
France
HPSP




– – – – – – – –
Greece
HESMO
Y Y – – Y Y – – -
Italy
AIOM
– – – – – – – Y –
Netherlands
NVMO
Y Y Y(48 hours) – – – – – –
Portugal
SPO,
Y Y Y Y Y Y – Y Y
Slovenia
OIL, SIO
Y – – Y Y Y Y – Y
Spain
SEOM
– Y – – Y – – – –
Sweden
SOF, RCCC
– – – – – – Y –
UK
NHS,NICE





Y Y Y Y Break/use
other units




Close to Home Y – – – Y Y Y –
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HCPs to minimize hospital
Circulation and surface contact
Non-COVID
Oncology circuits to be
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Y – – – Delay
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Y Y Y –
Slovenia
IOL
Y (only MTD with limited
stuff)
Y Y Y (we have in readiness a
COVID department with
ventilators)
Y (reduced and without
peroral contrast to



















– – y Y:Ref to POLST Y
Europe
ESMO
– – – – Y (according to priority
group)Frontiers in Oncology | www.frontiersin.org 11 November 2020 | VoAHM, Austrian Health Ministry; AMC, Austrian Medical Chamber; esp., especially; pt, patient; PPE, Personal Protective Equipment; resp., respiratory; CDC, Centers for Disease Control
and Prevention; HCP, Health Care Professional; T, Temperature; OP, Outpatient clinics.
Y*: issued by national guide and adopted by oncology society
“Y#”: presented as an option applied in several institutions but not as a recommendation in paragraph: “Additional prevention measures in hospitals and health centers”.lume 10 | Article 575148
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Croatia
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Y – – Y Y Y Y Y Y
France
HPSP
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Against – Y in
asymptomatic
– – – Y Dose reductions
Portugal
SPO
Y Y – Y Y Y Y Y Y Y
Slovenia
IOL
Y Y Y Y Y (for non-
curative only)










Y Y Y (consider
delay)
Y Y Y Y Y (for oral
drugs)
Steroids (low or hig
dose) ISs (e.g.,
everolimus)e
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Y Y Y (ITx) Y Y – – Y One negative test










Y Y Y Y for RT Y
3 courses
for oral Tx
Y – Y esp.in lung
and senior
pts
Y but no specific
guide ,” to discuss
with patient”




































































Y, Yes; -, Not available; GCSF, Granulocyte Colony stimulating factor;
Adjuvant; NR, Not Recommended; RBA, Risk-Benefit Assessment.r
e
Kamposioras et al. Covid-19 Recommendations From International Oncology SocietiesAPPENDIX TABLE 4 | Personal and Patients’ protective face mask.
Face mask/antiseptic for staff Type of Face mask for staff Face mask/
antiseptic for pts











Y (AHM) 1) SM or FFP2.
2) Suspected or confirmed COVID-19: PPE+FFP2.
Y SM or FF2
Belgium
BSMO
Y No specific mask type. Y No specific mask type.





Y SM or N95 or FFP2/3. – SM or textile mask.
Canada CCO Y 1) Staff who treats COVID-19 + pts who or "high-risk" pts for
virus transmission: personal protective equipment.
– –
Canada BCC Y 2) For high-risk of aerosolization procedures: Consider
performing a low-risk procedure.
If not possible, use N95 mask.
– –




2) Suspected or confirmed COVID-19: FFP2 respirator.
3) Suspected or confirmed COVID-19, for aerosol generating
procedures: FFP3 respirator.
Y 1) SM or textile mask).










Y* 1) SM. Tend to use FFP2.
2) Suspect COVID-19: FFP2 respirators, tend to use FFP2.
3) Confirmed COVID-19: FFP2 respirators.
Y* 1) No COVID-19 signs: SM
2) Suspect COVID-19: SM.
3) Confirmed COVID-19: SM
France
HPSP




Y 1) SM or FFP2.
2) Suspected or confirmed COVID-19: PPE+FFP2.
Y SM or FF2
Greece
HESMO
Y SM Y SM
Italy AIOM Y SM




Y No specific mask type. Y No specific mask type
Portugal
SPO
Y N/A Y N/A
Slovenia IOL Y a) Contact with COVID+ pts: IIR in combination with visir.
b) Intubation of surgical COVID-pts, <24 hours: mask FFP2
+visir.
c) Intubation >;24 hours COVID-pts : mask FFP3+visir.
Y SM
Spain SEOM Y SM Y Immunosuppressed pts:
FFP2 masks, with no valve.
Sweden SOF,
RCCC
Y (in assessment of patients
with COVID-19 symptoms).
No specific mask type. – No specific mask type.





Y (CDC) 1) SM + eye covering.
2) Suspected or confirmed COVID-19: n95.
Y SM or textile mask
Europe
ESMO
– SM Y SMFrontiers in Oncology | www.frontiersin.org 14 November 2020SM, Surgical Mask, pts, patients; N/A, Not available.| Volume 10 | Article 575148
